Next Article in Journal
Rationale for Extended Adjuvant Letrozole after Five Years of Tamoxifen in Postmenopausal Oestrogen Receptor–Positive Women with Early-Stage Breast Cancer
Previous Article in Journal
Cancer Stem Cells Revisited
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 12
Issue 4
10.3390/curroncol12040003
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Surrogate Endpoints in Colorectal Cancer

by
G. Browman
1,*,
A. Shah
2,
J. Ayoub
3,
R. Wong
4,
J. Maroun
5 and
G. Batist
6
1
Department of Oncology, McGill University and Montreal Centre for Experimental Therapeutics in Cancer, Sir Mortimer B. Davis–Jewish General Hospital, 3755 Cote St-Catherine Road, Montreal, QC H3T 1E2, Canada
2
BC Cancer Agency, Vancouver, BC, Canada
3
Notre Dame Hospital, Montreal, QC, Canada
4
St. Boniface General Hospital, Winnipeg, MN, Canada
5
The Ottawa Hospital Regional Cancer Centre, Ottawa, ON, Canada
6
Montreal Centre for Experimental Therapeutics in Cancer, Jewish General Hospital, and McGill University Department of Oncology, Montreal, QC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2005, 12(4), 136-146; https://doi.org/10.3390/curroncol12040003
Submission received: 19 September 2005 / Revised: 8 October 2005 / Accepted: 25 October 2005 / Published: 1 December 2005

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

There is ongoing debate about the criteria that are required for a new treatment to be approved for prescription and reimbursement and for clinicians to be convinced of that treatment’s true clinical utility [...]

Share and Cite

MDPI and ACS Style

Browman, G.; Shah, A.; Ayoub, J.; Wong, R.; Maroun, J.; Batist, G. Surrogate Endpoints in Colorectal Cancer. Curr. Oncol. 2005, 12, 136-146. https://doi.org/10.3390/curroncol12040003

AMA Style

Browman G, Shah A, Ayoub J, Wong R, Maroun J, Batist G. Surrogate Endpoints in Colorectal Cancer. Current Oncology. 2005; 12(4):136-146. https://doi.org/10.3390/curroncol12040003

Chicago/Turabian Style

Browman, G., A. Shah, J. Ayoub, R. Wong, J. Maroun, and G. Batist. 2005. "Surrogate Endpoints in Colorectal Cancer" Current Oncology 12, no. 4: 136-146. https://doi.org/10.3390/curroncol12040003

APA Style

Browman, G., Shah, A., Ayoub, J., Wong, R., Maroun, J., & Batist, G. (2005). Surrogate Endpoints in Colorectal Cancer. Current Oncology, 12(4), 136-146. https://doi.org/10.3390/curroncol12040003

Article Metrics

Back to TopTop